182 related articles for article (PubMed ID: 15771457)
21. Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers.
Vieira E; Huwyler J; Jolidon S; Knoflach F; Mutel V; Wichmann J
Bioorg Med Chem Lett; 2009 Mar; 19(6):1666-9. PubMed ID: 19233648
[TBL] [Abstract][Full Text] [Related]
22. Metabotropic glutamate 1 receptor distribution and occupancy in the rat brain: a quantitative autoradiographic study using [3H]R214127.
Lavreysen H; Pereira SN; Leysen JE; Langlois X; Lesage AS
Neuropharmacology; 2004 Apr; 46(5):609-19. PubMed ID: 14996538
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists.
Woltering TJ; Wichmann J; Goetschi E; Adam G; Kew JN; Knoflach F; Ballard TM; Huwyler J; Mutel V; Gatti S
Bioorg Med Chem Lett; 2008 Apr; 18(8):2725-9. PubMed ID: 18374569
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and evaluation of 1,2,4-methyltriazines as mGluR5 antagonists.
Olson JP; Gichinga MG; Butala E; Navarro HA; Gilmour BP; Carroll FI
Org Biomol Chem; 2011 Jun; 9(11):4276-86. PubMed ID: 21503289
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
26. 3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 3: Synthesis, metabolic stability, and biological evaluation of optically active analogs.
Asada M; Obitsu T; Kinoshita A; Nagase T; Yoshida T; Yamaura Y; Takizawa H; Yoshikawa K; Sato K; Narita M; Nakai H; Toda M; Tobe Y
Bioorg Med Chem; 2010 May; 18(9):3212-23. PubMed ID: 20385498
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists.
Liu S; Liu Y; Wang H; Ding Y; Wu H; Dong J; Wong A; Chen SH; Li G; Chan M; Sawyer N; Gervais FG; Henault M; Kargman S; Bedard LL; Han Y; Friesen R; Lobell RB; Stout DM
Bioorg Med Chem Lett; 2009 Oct; 19(19):5741-5. PubMed ID: 19713110
[TBL] [Abstract][Full Text] [Related]
28. Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.
Asada M; Obitsu T; Nagase T; Sugimoto I; Yamaura Y; Sato K; Narita M; Ohuchida S; Nakai H; Toda M
Bioorg Med Chem; 2009 Sep; 17(18):6567-82. PubMed ID: 19700331
[TBL] [Abstract][Full Text] [Related]
29. Nuclear localization of functional metabotropic glutamate receptor mGlu1 in HEK293 cells and cortical neurons: role in nuclear calcium mobilization and development.
Jong YJ; Schwetye KE; O'Malley KL
J Neurochem; 2007 Apr; 101(2):458-69. PubMed ID: 17250682
[TBL] [Abstract][Full Text] [Related]
30. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
Stern E; Muccioli GG; Bosier B; Hamtiaux L; Millet R; Poupaert JH; Hénichart JP; Depreux P; Goossens JF; Lambert DM
J Med Chem; 2007 Nov; 50(22):5471-84. PubMed ID: 17915849
[TBL] [Abstract][Full Text] [Related]
31. Novel small molecule bradykinin B2 receptor antagonists.
Gibson C; Schnatbaum K; Pfeifer JR; Locardi E; Paschke M; Reimer U; Richter U; Scharn D; Faussner A; Tradler T
J Med Chem; 2009 Jul; 52(14):4370-9. PubMed ID: 19552431
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and characterization of 8-ethynyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: new potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Part 1.
Woltering TJ; Adam G; Alanine A; Wichmann J; Knoflach F; Mutel V; Gatti S
Bioorg Med Chem Lett; 2007 Dec; 17(24):6811-5. PubMed ID: 17964783
[TBL] [Abstract][Full Text] [Related]
33. A new series of highly potent non-peptide bradykinin B2 receptor antagonists incorporating the 4-heteroarylquinoline framework. Improvement of aqueous solubility and new insights into species difference.
Sawada Y; Kayakiri H; Abe Y; Imai K; Mizutani T; Inamura N; Asano M; Aramori I; Hatori C; Katayama A; Oku T; Tanaka H
J Med Chem; 2004 Mar; 47(7):1617-30. PubMed ID: 15027853
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
Altenbach RJ; Liu H; Banfor PN; Browman KE; Fox GB; Fryer RM; Komater VA; Krueger KM; Marsh K; Miller TR; Pan JB; Pan L; Sun M; Thiffault C; Wetter J; Zhao C; Zhou D; Esbenshade TA; Hancock AA; Cowart MD
J Med Chem; 2007 Nov; 50(22):5439-48. PubMed ID: 17918921
[TBL] [Abstract][Full Text] [Related]
35. Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.
Hattori K; Toda S; Imanishi M; Itou S; Nakajima Y; Washizuka K; Araki T; Hamashima H; Tomishima Y; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Matsumura Y; Takamura F
J Med Chem; 2009 May; 52(9):3063-72. PubMed ID: 19366244
[TBL] [Abstract][Full Text] [Related]
36. Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonists.
Betts A; Atkinson F; Gardner I; Fox D; Webster R; Beaumont K; Morgan P
Drug Metab Dispos; 2007 Aug; 35(8):1435-45. PubMed ID: 17502340
[TBL] [Abstract][Full Text] [Related]
37. Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications.
Qiao JX; Wang TC; Wang GZ; Cheney DL; He K; Rendina AR; Xin B; Luettgen JM; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2007 Sep; 17(18):5041-8. PubMed ID: 17643988
[TBL] [Abstract][Full Text] [Related]
38. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT(1A) antagonists: the discovery of Lecozotan.
Childers WE; Abou-Gharbia MA; Kelly MG; Andree TH; Harrison BL; Ho DM; Hornby G; Huryn DM; Potestio L; Rosenzweig-Lipson SJ; Schmid J; Smith DL; Sukoff SJ; Zhang G; Schechter LE
J Med Chem; 2005 May; 48(10):3467-70. PubMed ID: 15887953
[TBL] [Abstract][Full Text] [Related]
40. Altered expression of G(q/11alpha) protein shapes mGlu1 and mGlu5 receptor-mediated single cell inositol 1,4,5-trisphosphate and Ca(2+) signaling.
Atkinson PJ; Young KW; Ennion SJ; Kew JN; Nahorski SR; Challiss RA
Mol Pharmacol; 2006 Jan; 69(1):174-84. PubMed ID: 16234485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
